STAT

Opinion: A dearth of physician innovators can derail new biomedical startups

As a physician shortage looms, few are talking about the lack of physician innovators and its effects on founding and growing biomedical startups.

Much has been made of the looming shortage of physicians. But there’s one place where the shortage is being felt acutely, is talked about even less, and the effects will ripple far into the future: the founding of new biomedical startups.

We live at a time when technology is dramatically transforming not just the field of biology but how biology-driven companies are built. It’s now entirely possible to create innovative and scalable new companies in the field with relatively modest initial funding. In other words, it’s salad days to be a bio startup, with so many new tools, data sources, and ideas at our disposal.

Yet there’s a moment of failure that crushes many such startups: when the new tool or technology connects with the real world of patients, physicians, medical records, hospitals, and insurers. That’s when a physician who can navigate the nuances

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min read
USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A J&J Cough Syrup, A Pfizer And Moderna Patent Suit, And More
A Johnson & Johnson children’s cough syrup found to contain unsafe levels of a toxic industrial solvent was sold in six African countries.

Related Books & Audiobooks